Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-IFNα for Locally Advanced/Metastatic Solid Tumors
NCT05699811Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MSC-IFNα in solid tumor (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Treatment Related Adverse Events at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
MSC-IFNα
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05699811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699811.